Soleno Therapeutics shares are trading higher after the company announced it received Breakthrough Therapy Designation from the FDA for DCCR extended-release tablets in Prader-Willi Syndrome.

Soleno Therapeutics Inc -1.39%

Soleno Therapeutics Inc

SLNO

41.90

-1.39%

Soleno Therapeutics shares are trading higher after the company announced it received Breakthrough Therapy Designation from the FDA for DCCR extended-release tablets in Prader-Willi Syndrome.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via